SAR and anti-mycobacterial activity of quinolones and triazoloquinolones: An update

Anti-Infective Agents

Volumn 11, Issue 1, 2013, Pages 75-89

  Briguglio, Irene ^a   Piras, Sandra ^a   Corona, Paola ^a   Pirisi, Maria Antonietta ^a   Jabes, Daniela ^b   Carta, Antonio ^a  

^a UNIVERSITY OF SASSARI   (Italy)

^b NeED Pharmaceuticals   (Italy)

Author keywords

Anti mycobacterial activity; DNA gyrase inhibitors; MDR TB; Quinolones; SAR analysis; Triazoloquinolones anti tubercular activity

Indexed keywords

AMIFLOXACIN; BAY Y 3114; CINOXACIN; CIPROFLOXACIN; CLINAFLOXACIN; DIFLOXACIN; DNA TOPOISOMERASE (ATP HYDROLYSING) A; DNA TOPOISOMERASE (ATP HYDROLYSING) B; ENOXACIN; ENROFLOXACIN; FLEROXACIN; GATIFLOXACIN; GEMIFLOXACIN; GREPAFLOXACIN; IRLOXACIN; LEVOFLOXACIN; LOMEFLOXACIN; MOXIFLOXACIN; MULTIDRUG RESISTANCE PROTEIN; NALIDIXIC ACID; NORFLOXACIN; OFLOXACIN; OXOLINIC ACID; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RUFLOXACIN; SITAFLOXACIN; SPARFLOXACIN; TOSUFLOXACIN; TROVAFLOXACIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; BACTERIAL GENOME; DIZZINESS; DRUG MECHANISM; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TRANSPORT; GASTROINTESTINAL SYMPTOM; GENE MUTATION; HEADACHE; HYPOGLYCEMIA; LIVER TOXICITY; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANT TUBERCULOSIS; NONHUMAN; PHOTOTOXICITY; PRURITUS; QT PROLONGATION; RASH; REVIEW; STRUCTURE ACTIVITY RELATION;

EID: 84872237811     PISSN: 22113525     EISSN: 22113533     Source Type: Journal    
DOI: 10.2174/22113626130109     Document Type: Review

References (199)

1. 2009 update, Tuberculosis facts, Geneva:World Health Organization, 2009.
2. WHO Global Tuberculosis Control Report, Geneva: World Health Organization, March 2002.
3. Global Tuberculosis Control, Geneva: World Health Organization, 2011.
4. Anti-tuberculosis drug resistance in the world: Third Global Report, Geneva: World Health Organization, 2008.
5. Ginsburg, A.S.; Grosset, J.H.; Bishai, W.R. Fluoroquinolones, tuberculosis, and resistance. Lancet Infect. Dis., 2003, 3, 432.
6. Alland, D.; Kalkut, G.E.; Moss, A.R.; McAdam, R.A.; Hahn, J.A.; Bosworth, W.; Drucker, E.; Bloom, B.R. Transmission of tuberculosis in New York City. An analysis by DNA fingerprinting and conventional epidemiologic methods. N. Engl. J. Med., 1994, 330, 1710-1716.
7. Global tuberculosis control: a short update to the 2010 Report. Geneva: World Health Organization, 2010.
8. Getahun H.; Gunneberg C.; Granich R.; Nunn P. HIV infectionassociated tuberculosis: the epidemiology and the response. Clin. Infect. Dis., 2010, 50(3), 201-207.
9. Guidelines for intensified tuberculosis case-finding and isoniazid preventive therapy for people living with HIV in resourceconstrained settings, Geneva:World Health Organization, 2011.
10. Whalen, C.; Horsburgh, C.R.; Hom, D.; Lahart, C.; Simberkoff, M.; Ellner, J. Accelerated course of human immunodeficiency virus infection after tuberculosis. Am. J. Respir. Crit. Care Med., 1995, 51, 129-135.
11. Hart, C.A.; Beeching, N.J.; Duerden, B.I. Tuberculosis into the next century. Proceedings of a symposium held on 4 February 1995 at the Liverpool School of Medicine. J. Med. Microbiol., 1996, 44, 1-34.
12. Young, L.S. Mycobacterial infections in immunocompromised patients. Curr. Opin. Infect. Dis., 1996, 9, 240-245.
13. Tomioka, H.; Sato, K.; Kajitani, H.; Akaki, T.; Shishido, S. Comparative antimicrobial activities of the newly synthesized quinolone WQ-3034, levofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex. Antimicrob. Agents Chemother., 2000, 44, 283-286.
14. Inderlied, C.B.; Kemper, C.A.; Bermudez, L.E. The Mycobacterium avium complex. Clin. Microbiol. Rev., 1993, 6, 266-310.
15. Falkinham, J.O. Epidemiology of infection by nontuberculous mycobacteria. Clin. Microbiol. Rev., 1996, 9, 177-215.
16. Sakatani, M. Nontuberculous mycobacteriosis (NTM) in Japan-epidemiologic and clinical study. Kekkaku, 1994, 69, 119-124.
17. Ellner, J.J.; Goldberger, M.J.; Parenti, D.M. Mycobacterium avium infection and AIDS: a therapeutic dilemma in rapid evolution. Infect Dis., 1991, 163, 1326-1335.
18. Styblo, K. Recent advances in epidemiological research in tuberculosis. Indian. J. Chest. Dis. Allied Sci., 1982, 24, 101-107.
19. Treatment of pulmonary tuberculosis with para-aminosalicylic acid and Streptomycin, British Medical Research Council, BMJ, 1949, 2, 1521.
20. th ed. Geneva:World Health Organization, 2009.
21. Akashdeep S. Fluoroquinolones should not be the first-line antibiotics to treat community acquired Pneumonia in areas of Tuberculosis endemicity. Clin. Infect Dis., 2007, 45(1), 133.
22. Migliori G.B.; Lange C.; Girardi E.; Centis R.; Besozzi G.; Kliiman K.; Codecasa L.R.; Spanevello A.; Cirillo D.M.; SMIRA/TBNET Study Group. Fluoroquinolones: are they essential to treat multidrugresistant tuberculosis? Eur. Respir. J., 2008, 31, 904-905.
23. Mugnaini C.; Pasquini S.; Corelli F. The 4-quinolone-3-carboxylic acid motif as a multivalent scaffold in medicinal chemistry. Curr. Med. Chem., 2009, 16, 1746-1767.
24. Ahmed A.; Daneshtalab M. Nonclassical biological activities of quinolone derivatives. J Pharm. Pharmaceut. Sci., 2012, 15(1), 52-72.
25. Nora de Souza, M.V.; Rocha Alves Vasconcelos, T.; Viera de Almeida, M.; Cardoso, S.H. Fluoroquinolones: an important class of antibiotics against tuberculosis. Curr. Med. Chem., 2006, 13, 455-463.
26. Van den Boogaard J.; Kibiki G.S.; Kisanga E.R.; Boeree M.J.; Aarnoutse R.E. New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development. Antimicrob. Agents Chemother., 2009, 53, 849-862.
27. Guidelines for the Programmatic Management of Drug-resistant Tuberculosis. Geneva: World Health Organization, 2008.
28. Devasia R.A.; Blackman A.; May C.; Eden S.; Smith T.; Hooper N.; Maruri F.; Stratton C.; Shintani A.; Sterling T.R. Fluoroquinolone resistance in Mycobacterium tuberculosis: an assessment of MGIT 960, MODS and nitrate reductase assay and fluoroquinolone cross-resistance. J. Antimicrob. Chemother., 2009, 63, 1173-1178.
29. Strass C. Fluoroquinolone antibiotics: properties of the class and individual agents. Clin Ther 1992, 14, 348-375.
30. Appelbaum, P.C.; Hunter, P.A. The fluoroquinolone antibacterials: past, present and future perspectives. Int. J. Antimicrob., 2000, 16, 5-15.
31. Sharma, A.K.; Khosla, R.; Kelaand, A.K.; Mehta, V.L. Fluoroquinolones: antimicrobial agents of the 90's. Indian J. Pharm., 1994, 26, 249-261.
32. Zhanel, G.G.; Ennis, K.; Vercaigne, L.; Walkty, A.; Gin, A.S.; Embil, J.; Smith, H.; Hobon, D.J. A critical review of the fluoroquinolones: focus on respiratory infections. Drugs, 2002, 62, 13-59.
33. Andriole, V.T. The future of the quinolones. Drugs, 1993, 45, 1-7.
34. Stein, G.E. Pharmacokinetics and pharmacodynamics of newer fluoroquinolones. Clin. Infect. Dis., 1996, 23, 19-24.
35. Wolfson, J.S.; Hooper, D.C. Fluoroquinolone antimicrobial agents. Clin. Microbiol. Rev., 1989, 2, 378-424.
36. Domagala, J.M. Structure-activity and structure-side-effect relationships for the quinolone antibacterials. J. Antimicrob. Chemother., 1994. 33, 685-706.
37. Jacobs, M.R. Fluoroquinolones as chemotherapeutics against mycobacterial infections. Current Pharm. Des., 2004, 10, 3213-3220.
38. Berning, S.E. The role of fluoroquinolones in tuberculosis today. Drugs, 2001, 61, 9-18.
39. Gillespie, S.H.; Morrissey, I.; Everett, D. A comparison of the bactericidal activity of quinolone antibiotics in a Mycobacterium fortuitum model J. Med. Microbiol., 2001, 50, 565-570.
40. Bartlett, J.G.; Dowell, S.F.; Mandell, L.A. Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America. Clin. Infect. Dis., 2000, 31, 347-382.
41. Huang, E.S.; Stafford, R.S. National patterns in the treatment of urinary tract infections in women by ambulatory care physicians. Arch. Intern. Med., 2002, 162, 41-47.
42. Tomioka, H. Prospects for development of new antimycobacterial drugs. J. Infect. Chemother., 2000, 6, 8-20.
43. Grassi, C. New drugs for tuberculosis. Exp. Opin. Invest. Drugs, 1997, 6, 1211-1226.
44. Yew, W.W.; Chau, C.H. New antimycobacterial agents. Monaldi. Arch. Chest. Dis., 1996, 51, 394-404.
45. Hooper, D.C.; Wolfson, J.S. The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans. Antimicrob. Agents. Chemother., 1985, 29, 716-721.
46. Leysen, D.C.; Haemers, A.; Pattyn, S.R. Mycobacteria and the new quinolones. Antimicrob. Agents. Chemother., 1989, 33, 1-5.
47. Alangaden, G.J.; Lerner, S.A. The clinical use of fluoroquinolones for the treatment of mycobacterial diseases. Clin. Infect. Dis., 1997, 25, 1213-1221.
48. Kim, J.H.; Kang, J.A.;, Kim, Y.G.; Kim, J.W.; Lee J.H.; Choi E.C.; Kim B.K. In vitro and in vivo antibacterial efficacies of CFC-222, a new fluoroquinonole. Antimicrob. Agents Chemother., 1997, 41, 2209-2213.
49. Jones, M.E.; Critchley, A.; Karlosky, J.A.; Blosser-Middleton, R.S.; Schmitz, F.J.; Thornsberry C.; Sahm, D.F. In vitro activities of novel nonfluorinated quinolones PGE 9262932 and PGE 9509924 against clinical isolates of Staphylococcus aureus and Streptococcus pneumoniae with defined mutations in DNA gyrase and topoisomerase IV. Antimicrob. Agents Chemother., 2002, 46, 1651-1657.
50. Zhang, Y. Advances in the treatment of tuberculosis. Clin. Pharmacol. Ther., 2007, 82, 595-600.
51. Von Groll A., Martin A., Jureen P., Hoffner S., Vandamme P., Portaels F., Palomino J.C., da Silva P.A. Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. Antimicrob. Agents Chemother., 2009, 53, 4498-4500.
52. Tomioka, H. J. Prospects for development of new antimycobacterial drugs. Infect. Chemother., 2000, 6, 8-20.
53. Richeldi, L.; Covi, M.; Ferrara, G.; Franco, F.; Vailati, P.; Meschiari, E.; Fabbri, L.M.; Velluti, G. Clinical use of Levofloxacin in the long-term treatment of drug resistant tuberculosis. Monaldi. Arch. Chest. Dis., 2002, 57, 39-43.
54. Berning, S.E. The role of fluoroquinolones in tuberculosis today. Drugs, 2001, 61, 9-18.
55. Alvirez-Freites, E.J.; Carter, J.L.; Cynamon, M.H. In vitro and in vivo activities of gatifloxacin against Mycobacterium tuberculosis. Antimicrob. Agents Chemother., 2002, 46, 1022-1025.
56. Rodriguez, J.C.; Cebrian, L.; Lopez, M.; Ruiz, M.; Royo, G. Usefulness of various antibiotics against Mycobacterium aviumintracellulare, measured by their mutant prevention concentration. Int. J. Antimicrob. Agents, 2005, 25, 221-225.
57. Woods, G.L.; Williams-Bouyer, B.A.; Wallace, R.J.; Brown-Elliott Jr, B.A.; Witebsky, F.G.; Conville, P.S.; Plaunt, M.; Hall, G.; Aralar, P.; Inderlied, C. Multisite reproducibility of results obtained by two broth dilution methods for susceptibility testing of Mycobacterium avium complex. J. Clin. Microbiol., 2003, 41, 627-631.
58. Horiguchi, T.; Kondo, R.; Miyazaki, J.; Shiga, M.; Sugiyama, M.; Handa, M.; Munekata, E. Antibacterial activity and clinical efficacy of sparfloxacin in Mycobacterium avium-intracellulare complex infection. J. Intern. Med. Res., 2004, 32, 530-539.
59. Kobashi, Y.; Yoshida, K.; Miyashita, N.;·Niki, Y.;·Oka, M. Relationship between clinical efficacy of treatment of pulmonary Mycobacterium avium complex disease and drug-sensitivity testing of Mycobacterium avium complex isolates. J. Infect. Chemother., 2006, 12, 195-202.
60. Tomioka, H.; Sano, C.; Sato, K.; Shimizu, T. Antimicrobial activities of clarithromycin, gatifloxacin and sitafloxacin, in combination with various antimycobacterial drugs against extracellular and intramacrophage Mycobacterium avium complex. Int. J. Antimicrob. Agents, 2002, 19, 139-145.
61. Casal, M.; Gutierrez, J.; Gonzales, J.; Ruiz, P. In vitro susceptibility of Mycobacterium tuberculosis to ofloxacin and ciprofloxacin in combination with rifampin and isoniazid. Chemioterapia, 1987, 6, 437-439.
62. Rastogi, N.; Goh, K.S.; Bryskler, A.; Devallois, A. In vitro activities of levofloxacin used alone and in combination with first-and second-line antituberculous drugs against Mycobacterium tuberculosis. Antimicrob. Agents Chemother., 1996, 40,1610-1616.
63. Lu, T.; Drlica, K. In vitro activity of C-8-methoxy fluoroquinolones against mycobacteria when combined with antituberculosis agents. J. Antimicrob. Chemother., 2003, 52, 1025.
64. Alvirez-Freites, E.J.; Carter, J.L.; Cynamon, M.H. In vitro and in vivo activities of gatifloxacin against Mycobacterium tuberculosis. Antimicrob. Agents Chemother., 2002, 46, 1022-1025.
65. Lalande, V.; Truffot-Pernot, C.; Pacally-Moulin, A.; Grosset, J.; Ji, B. Powerful bactericidal activity of sparfloxacin (AT-4140) against Mycobacterium tuberculosis in mice. Antimicrob. Agents Chemother., 1993, 37, 407-413.
66. Miyazaki, E.; Miyazaki, M.; Chen, J.M.; Chaisson, R.E.; Bishai, W.R. Moxifloxacin (BAY12-8039), a new 8-methoxyquinolone, is active in a mouse model of tuberculosis. Antimicrob. Agents Chemother., 1999, 43, 85-89.
67. Fattorini, L.; Tan, D.; Iona, E.; Mattei, M.; Giannoni, F.; Brunori L.; Recchia, S.; Orefici, G. Activities of moxifloxacin alone and in combination with other antimicrobial agents against multidrugresistant Mycobacterium tuberculosis infection in BALB/c mice. Antimicrob. Agents Chemother., 2003, 47, 360-362.
68. Cynamon, M.H.; Sklaney, M. Gatifloxacin and ethionamide as the foundation for therapy of tuberculosis. Antimicrob. Agents Chemother., 2003, 47, 2442-2444.
69. Tomioka, H.; Sato, K.; Shimizu T.; Sano, C. Anti-Mycobacterium tuberculosis activities of new fluoroquinolones in combination with other antituberculous drugs. J. Infect., 2002, 44, 160-165.
70. Van der Auwera, P.; Matsumoto T.; Husson, M. Intraphagocytic penetration of antibiotics. J. Antimicrob. Chemother., 1988, 22, 185-192.
71. Rastogi, N.; Labrousse V.; Goh, K.S. In vitro activities of fourteen antimicrobial agents against drug susceptible and resistant clinical isolates of Mycobacterium tuberculosis and comparative intracellular activities against the virulent H37Rv strain in human macrophages. Curr. Microbiol., 1996, 33, 167-175.
72. Crowle, A.J.; Elkins, N.; May, M.H. Effectiveness of ofloxacin against Mycobacterium tuberculosis and Mycobacterium avium, and rifampin against M. tuberculosis in cultured human macrophages. Am. Rev. Respir. Dis., 1988, 137, 1141-1146.
73. Mor, N.; Vanderkolk, J.; Heifets, L. Inhibitory and bactericidal activities of levofloxacin against Mycobacterium tuberculosis in vitro and in human macrophages. Antimicrob. Agents Chemother., 1994, 38, 1161-1164.
74. Sbarbaro, J.A.; Iseman, M.D.; Crowle A.J. Combined effect of pyrazinamide and ofloxacin within the human macrophage. Tuber. Lung Dis., 1996, 77, 491-495.
75. Tomioka, H. Current status of some antituberculosis drugs and the development of new antituberculous agents with special reference to their in vitro and in vivo antimicrobial activities. Curr. Pharm. Des., 2006, 12, 4047-4070.
76. Sano, K.; Tomioka, H.; Sato, K.; Sano, C.; Kawauchi, H.; Cai, S.; Shimizu, T. Interaction of antimycobacterial drugs with the anti-Mycobacterium avium complex effects of antimicrobial effectors, reactive oxygen intermediates, reactive nitrogen intermediates, and free fatty acids produced by macrophages. Antimicrob. Agents Chemother., 2004, 48, 2132-2139.
77. Yew, W.W.; Kwan, S.Y.; Ma, W.K.; Chau, P.Y. In-vitro activity of ofloxacin against Mycobacterium tuberculosis and its clinical efficacy in multiply resistant pulmonary tuberculosis. J. Antimicrob. Chemother., 1990, 26, 227-236.
78. Cambau, E.; Jarlier, V. Resistance to quinolones in mycobacteria. Res. Microbiol., 1996, 147, 52-59.
79. Tsukamura, M.; Nakamura, E.; Yoshii, S.; Amano, H. Therapeutic effect of a new antibacterial substance ofloxacin (DL8280) on pulmonary tuberculosis. Am. Rev. Respir. Dis., 1985, 131, 352-356.
80. Ginsburg, A.S.; Hooper, N.; Parrish, N.; Dooley, K.E.; Dorman, S.E.; Booth, J.; Diener-West, M.; Merz, W.G.; Bishai, W.R.; Sterling, T.R. Fluoroquinolone resistance in patients with newly diagnosed tuberculosis. Clin. Infect. Dis., 2003, 37, 1448-1452.
81. Anquetin, G.; Greiner, J.; Mahmoudi, N.; Santillana-Hayat, M.; Gozalbes, R.; Farhati, K.; Derouin, F.; Aubry, A.; Cambau, E.; Vierling, P. Design, synthesis and activity against Toxoplasma gondii, Plasmodium spp., and Mycobacterium tuberculosis of new 6-fluoroquinolones. Eur. J. Med. Chem., 2006, 41, 1478-1493.
82. Drlica, K.; Zhao, X. DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol. Molec. Biol. Reviews, 1997, 61, 377-392.
83. Hooper, DC. Emerging mechanisms of fluoroquinolone resistance. Emerg. Infect. Dis,. 2001, 7, 337-341.
84. Alovero, F.L.; Pan, X.S.; Morris, J.E.; Manzo, R.H.; Fisher, L.M. Engineering the specificity of antibacterial fluoroquinolones: benzenesulfonamide modifications at C-7 of ciprofloxacin change its primary target in Streptococcus pneumoniae from topoisomerase IV to gyrase. Antimicrob. Agents Chemother., 2000, 44, 320-325.
85. Barnard, F.M.; Maxwell, A. Interaction between DNA gyrase and quinolones: effects of alanine mutations at GyrA subunit residues Ser(83) and Asp(87). Antimicrob. Agents Chemother., 2001, 45, 1994-2000.
86. Champoux, J.J. DNA topoisomerases: structure, function, and mechanism. Annu. Rev. Biochem., 2001, 70, 369-413.
87. Mitscher, L.A. Bacterial topoisomerase inhibitors: quinolone and pyridone antibacterial agents. Chem. Rev., 2005, 105, 559-592.
88. Bryan, L.E.; Bedard, J.; Wong, S.; Chamberland, S. Quinolone antimicrobial agents: mechanism of action and resistance development. Clin. Invest. Med., 1989, 12, 14-19.
89. Cole, S.T.; Brosch, R.; Parkhill, J.; Garnier, T.; Churcher, C.; Harris, D.; Gordon, SV.; Eiglmeier, K.; Gas, S.; Barry, C.E.; Tekaia, F.; Badcock, K.; Basham, D.; Brown, D.; Chillingworth, T.; Connor, R.; Davies, R.; Devlin, K.; Feltwell, T.; Gentles, S.; Hamlin, N.; Holroyd, S.; Hornsby, T.; Jagels, K.; Krogh, A.; McLean, J.; Moule, S.; Murphy, L.; Oliver, K.; Osborne, J.; Quail, M.A.; Rajandream, M.A.; Rogers, J.; Rutter, S.; Seeger, K.; Skelton, J.; Squares, R.; Squares, S.; Sulston, J.E.; Taylor, K.; Whitehead, S.; Barrell, B.G. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature, 1998, 393, 537-544.
90. Corbett, K.D.; Berger, J.M. Structure, molecular mechanisms, and evolutionary relationships in DNA topoisomerases. Annu. Rev. Biophys. Biomol. Struct., 2004, 33, 95-118.
91. Levine, C.; Hiasa, H.; Marians, K.J. DNA gyrase and topoisomerase IV: biochemical activities, physiological roles during chromosome replication, and drug sensitivities. Biochim. Biophys. Acta, 1998, 1400, 29-43.
92. Smith, J.T.; Lewin, C.S. Chemistry and mechanisms of action of the quinolone antibacterials, in the quinolones. Andiole, V.T. ed.; Academic Press, London, 1988, 82.
93. Hooper, D.C.; Wolfson, J.S. Fluoroquinolone antimicrobial agents. N. Engl. J. Med., 1991, 324, 384-394.
94. Brighty, K.E.; Gootz, T.D. The chemistry and biological profile of trovafloxacin. J. Antimicrob. Chemother., 1997, 39 B, 1-14.
95. Hooper, D.C. Quinolone mode of action. Drugs, 1995, 49, 10-15.
96. Bryan, L.E.; Bedard, J.; Wong, S.; Chamberland, S. Quinolone antimicrobial agents: mechanism of action and resistance development. Clin. Invest. Med., 1989, 12, 14-19.
97. Yoshida, H.; Nakamura, M.; Bogaki, M.; Ito, H.; Kojima, T.; Hattori, H.; Nakamura, S. Mechanism of action of quinolones against Escherichia coli DNA gyrase. Antimicrob. Agents Chemother., 1993, 37, 839-845.
98. Roblin, D. The clinical development of quinolone antibacterials. Int. J. Pharm. Med., 1999, 13, 83-90.
99. Peng, H.; Marians, K.J. Escherichia coli topoisomerase IV. Purification, characterization, subunit structure, and subunit interactions. J. Biol. Chem., 1993, 268, 24481-90.
100. Kato, J.; Nishimura, Y.; Imamura, R.; Niki, H.; Hiraga S.; Suzuki, H. New topoisomerase essential for chromosome segregation in E. coli. Cell., 1990, 63, 393-404.
101. Saiki, A.Y.; Shen, L.L.; Chen, C.N.; Baranowski, J.; Lerner, C.G. DNA cleavage activities of Staphylococcus aureus gyrase and topoisomerase IV stimulated by quinolones and 2-pyridones. Antimicrob. Agents Chemother., 1999, 43, 1574-1577.
102. Blanche, R.; Cameron, B.; Bernard, F.X.; Maton, L.; Manse, B.; Ferrero, L.; Ratet, N.; Lecoq, C.; Goniot, A.; Bisch, D.; Crouzet, J. Differential behaviors of Staphylococcus aureus and Escherichia coli type II DNA topoisomerases. Antimicrob. Agents Chemother., 1996, 40, 2714-2720.
103. Kitamura, A.; Hoshino, K.; Kimura, Y.; Hayakawa, I.; Sato, K. Contribution of the C-8 substituent of DU-6859a, a new potent fluoroquinolone, to its activity against DNA gyrase mutants of Pseudomonas aeruginosa. Antimicrob. Agents Chemother., 1995, 39, 1467-1471.
104. Pan, X.S.; Fisher, L.M. Streptococcus pneumoniae DNA gyrase and topoisomerase IV: overexpression, purification, and differential inhibition by fluoroquinolones. Antimicrob. Agents Chemother., 1999, 43, 1129-1136.
105. Varon, E.; Janoir, C.; Kitzis, M.D.; Gutmann, L. ParC and GyrA may be interchangeable initial targets of some fluoroquinolones in Streptococcus pneumoniae. Antimicrob. Agents Chemother., 1999, 43, 302-306.
106. Hooper, D.C. Mechanisms of action and resistance of older and newer fluoroquinolones. Clin. Infect. Dis., 2000, 31, 24-28.
107. Pestova, E.; Millichap, J.J.; Noskin, G.A.; Peterson, L.R. Intracellular targets of moxifloxacin: a comparison with other fluoroquinolones. J. Antimicrob. Chemother., 2000, 45, 583-590.
108. Fukuda, H.; Hiramatsu, K. Primary targets of fluoroquinolones in Streptococcus pneumoniae. Antimicrob. Agents Chemother., 1999, 43, 410-412.
109. Aubry A., Pan X.S., Fisher L.M., Jarlier V., Cambau E. Mycobacterium tuberculosis DNA gyrase: interaction with quinolones and correlation with antimycobacterial drug activity. Antimicrob. Agents Chemother., 2004, 48, 1281-1288.
110. Maxwell A. DNA gyrase as a drug target. Trends Microbiol., 1997, 5, 102-109.
111. Barnard F.M., Maxwell A. Interaction between DNA gyrase and quinolones: effects of alanine mutations at GyrA subunit residues Ser(83) and Asp(87). Antimicrob. Agents Chemother., 2001, 45, 1994-2000.
112. Sun Z., Zhang J., Zhang X., Wang S., Zhang Y., Li. C. Comparison of gyrA gene mutations between laboratory-selected ofloxacinresistant Mycobacterium tuberculosis strains and clinical isolates. Int. J. Antimicrob. Agents, 2008, 31, 115-121.
113. Piton J., Petrella S., Delarue M., André-Leroux G., Jarlier V., Aubry A., Mayer C. Structural insights into the quinolone resistance mechanism of Mycobacterium tuberculosis DNA gyrase. PLoS ONE, 2010, 5(8), e12245.
114. Takiff H.E., Salazar L., Guerrero C., Philipp W., Huang W.M., Kreiswirth B., Cole S.T., Jacobs W.R., Jr, Telenti A. Cloning and nucleotide sequence of Mycobacterium tuberculosis gyrA and gyrB genes and detection of quinolone resistance mutations. Antimicrob. Agents Chemother., 1994, 38, 773-780.
115. Aubry A., Veziris N., Cambau E., Truffot-Pernot C., Jarlier V., Fisher M. Novel gyrase mutations in quinolone-resistant and-hypersusceptible clinical isolates of Mycobacterium tuberculosis: functional analysis of mutant enzymes. Antimicrob. Agents Chemother., 2006, 50, 104-112.
116. Veziris N., Martin C., Brossier F., Bonnaud F., Denis F., Aubry A. Treatment failure in a case of extensively drug-resistant tuberculosis associated with selection of a GyrB mutant causing fluoroquinolone resistance. Eur. J. Clin. Microbiol. Infect. Dis., 2007, 26, 423-425.
117. Sullivan, E.A.; Kreiswirth, B.N.; Palumbo, L.; Kapur, V.; Musser, J.M.; Ebrahimzadeh, A.; Frieden, T.R. Emergence of fluoroquinolone-resistant tuberculosis in New York City. Lancet, 1995, 345, 1148-1150.
118. Williams, K.J.; Chan, R.; Piddock, L.J. gyrA of ofloxacin-resistant clinical isolates of Mycobacterium tuberculosis from Hong Kong. J. Antimicrob. Chemother., 1996, 37, 1032-1034.
119. Xu, C.; Kreiswirth, B.N.; Sreevatsan, S.; Musser, J.M.; Drlika, K. Fluoroquinolone resistance associated with specific gyrase mutations in clinical isolates of multidrug-resistant Mycobacterium tuberculosis. J. Infect. Dis., 1996, 174, 1127-1130.
120. Perlman, D.C.; El Sadr, W.M.; Heifets, L.B.; Nelson, E.T.; Matts, J.P.; Chirgwin, K.; Salomon, N.; Telzak, E.E.; Klein, O.; Kreiswirth, B.N.; Musser, J.M.; Hafner, R. Susceptibility to levofloxacin of Myocobacterium tuberculosis isolates from patients with HIVrelated tuberculosis and characterization of a strain with levofloxacin monoresistance. Community Programs for Clinical Research on AIDS 019 and the AIDS Clinical Trials Group 222 Protocol Team. AIDS, 1997, 11, 1473-1478.
121. Ruiz, J. Mechanisms of resistance to quinolones: target alterations, decreased accumulation and DNA gyrase protection. J. Antimicrob. Chemother., 2003, 51, 1109-1117.
122. Alangaden, G.J.; Manavathu, E.K.; Vakulenko, S.B.; Zvonok, N.M.; Lerner, S.A. Characterization of fluoroquinolone-resistant mutant strains of Mycobacterium tuberculosis selected in the laboratory and isolated from patients. Antimicrob. Agents Chemother., 1995, 39, 1700-1703.
123. Kocagoz, T.; Hackbarth, C.J.; Unsal, I.; Rosemberg, E.Y.; Nikaido, H.;Chambers, H.F. Gyrase mutations in laboratory-selected, fluoroquinolone-resistant mutants of Mycobacterium tuberculosis H37Ra. Antimicrob. Agents Chemother., 1996, 40, 1768-1774.
124. Foroumadi, A.; Oboudiat, M.; Emami, S.; Karimollah, A.; Saghaee, L.; Moshafi, M.H.; Shafiee, A. Synthesis and antibacterial activity of N-[2-[5-(methylthio)thiophen-2-yl]-2-oxoethyl]and N-[2-[5-(methylthio)thiophen-2-yl]-2-(oxyimino)ethyl]piperazinylquinolone derivatives. Bioorg. Med. Chem., 2006, 14, 3421-3427.
125. Cambau, E.; Sougakoff, W.; Besson, M.; Truffot-Pernot, C.; Grosset, J.; Jarlier. V. Selection of a gyrA mutant of Mycobacterium tuberculosis resistant to fluoroquinolones during treatment with ofloxacin. J. Infect. Dis., 1994, 170, 479-483.
126. Pitaksajjakul, P.; Wongwit, W.; Punprasit, W.; Eampokalap, B.; Peacock, S.; Ramasoota, P. Mutations in the gyrA and gyrB genes of fluoroquinolone-resistant Mycobacterium tuberculosis from TB patients in Thailand. Southeast Asian J. Trop. Med: Public Health, 2005, 36, 228-237.
127. Aubry, A.; Veziris, N.; Cambau, E.; Truffot-Pernot, C.; Jarlier, V.; Fisher, L.M. Novel gyrase mutations in quinolone-resistant and-hypersusceptible clinical isolates of Mycobacterium tuberculosis: functional analysis of mutant enzymes. Antimicrob. Agents Chemother., 2006, 50, 104-112.
128. Banerjee, S.K.; Bhatt, K.; Rana, S.; Misra, P.; Chakraborti, P.K. Involvement of an efflux system in mediating high level of fluoroquinolone resistance in Mycobacterium smegmatis. Biochem. Biophys. Res. Commun., 1996, 226, 362-368.
129. Acar, J.F.; Goldstein, F.W. Trends in bacterial resistance to fluoroquinolones. Clin. Infect. Dis., 1997, 24, 67-73.
130. Richard, P.; Delangle, M.H.; Merrien, D.; Barillé, S.; Reynaud, A.; Minozzi, C.; Richet, H. Fluoroquinolone use and fluoroquinolone resistance: is there an association? Clin. Infect. Dis., 1994, 19, 54-59.
131. Lee, A.S.; Tang, L.L.; Lim, I.H.; Wong, S.Y. Characterization of pyrazinamide and ofloxacin resistance among drug resistant Mycobacterium tuberculosis isolates from Singapore. Int. J. Infect. Dis., 2002, 6, 48-51.
132. De Rossi, E.; Aìnsa, J.A.; Riccardi, G. Role of mycobacterial efflux transporters in drug resistance: an unresolved question. FEMS Microbiol. Rev., 2006, 30, 36-52.
133. Li, X.Z.; Nikaido, H. Efflux-mediated drug resistance in bacteria. Drugs, 2004, 64, 159-204.
134. De Rossi, E.; Arrigo, P.; Bellinzoni, M.; Silva, P.A.; Martin, C.; Ainsa, J.A.; Guglierame, P.; Riccardi, G. The multidrug transporters belonging to major facilitator superfamily in Mycobacterium tuberculosis. Mol. Med., 2002, 8, 714.-724.
135. Liu, J.; Takiff, H.E.; Nikaido, H. Active efflux of fluoroquinolones in Mycobacterium smegmatis mediated by LfrA, a multidrug efflux pump. J. Bacteriol., 1996, 178, 3791-3795.
136. Takiff, H.E.; Cimino, M.; Musso, M.C.; Weisbrod, T.; Martinez, R.; Delgado, M.B.; Salazar, L.; Bloom, B.R.; Jacobs Jr., W.R. Efflux pump of the proton antiporter family confers low-level fluoroquinolone resistance in Mycobacterium smegmatis Proc. Natl. Acad. Sci. USA., 1996, 93, 362-366.
137. Pasca, M.R.; Guglierame, P.; Arcesi, F.; Bellinzoni, M.; De Rossi, E.; Riccardi, G. Rv2686c-Rv2687c-Rv2688c, an ABC fluoroquinolone efflux pump in Mycobacterium tuberculosis. Antimicrob. Agents Chemother., 2004, 48, 3175-3178.
138. Compendium of Pharmaceuticals and Specialties. 35th ed. Ottawa: Canadian Pharmacists Association, 2000.
139. DeAbate, C.A.; McIvor, R.A.; Elvaine, P. Gatifloxacin vs cefuroxime axetil in patients with acute exacerbations of chronic bronchitis J. Respir. Dis., 1999, 20, 23-29.
140. Ramirez, A.; Molina, J.; Holmann, A. Gatifloxacin treatment in patients with acute exacerbations of chronic bronchitis:clinical trial resultsJ. Respir. Dis., 1999, 20, 30-39.
141. Fogarty, C.; McAdoo, M.A.; Paster, R. Gatifloxacin vs. clarithromycin in the management of acute sinusitis. J. Respir. Dis., 1999, 20, 17-22.
142. Lopez-Sisniega, J.A.; Jones, R.W.; Kaminszczik, G. Treating acute, uncomplicated bacterial sinusitis with gatifloxacin. J. Respir. Dis., 1999, 20, 11-16.
143. DeAbate, C.A.; Russell, M.; McElvaine, P. Safety and efficacy of oral levofloxacin versus cefuroxime axetil in acute bacterial exacerbation of chronic bronchitis. Respir. Care., 1997, 42, 206-213.
144. Habib, M.P.; Russell, M.; De Abate, C.A. Multicenter, randomized study comparing efficacy and safety of oral levofloxacin and cefaclor in the treatment of acute exacerbations of cheronic bronchitis. Infect. Dis. Clin. Practice, 1998, 7, 1-9.
145. Bird, N.; Lewis, A.; Montague, T. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, 2000, Sep 17-20, Toronto (ON).
146. Welling, L.E.; Burke, C.L.; Tack, K.J. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1999, Sep 26-29; San Francisco (CA).
147. Lipsky, B.A.; Dorr, M.B.; Magner, D.J. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1996, Sep 15-18; New Orleans (CA).
148. Products, EAFTEOM, Public statement on trovafloxacin/alatrofloxacin: recommendation to suspend the marketing authorisation in the European Union, 1999, London.
149. Lucena, M.I.; Andrade, R.J.; Rodrigo, L.; Salmeron, J.; Alvarez, A.; Lopez-Garrido, M.J.; Camargo, R.;Alcantàra, R. Trovafloxacininduced acute hepatitis. Clin. Infect. Dis., 2000, 30, 400-401.
150. Yew, W.W.; Wong, C.F.; Wong P.C.; Lee, J.; Chau, C.H. Adverse neurological reactions in patients with multidrug-resistant pulmonary tuberculosis after administration of cycloserine and ofloxacin. Clin. Infect. Dis., 1993, 17, 288-289.
151. Horn, D.L.; Hewlett Jr, D.; Alfalla, C.; Peterson S.; Opal, S.M. Limited tolerance of ofloxacin and pyrazinamide prophylaxis against tuberculosis. N. Engl. J. Med., 1994, 330, 1241.
152. Ridzon, R.; Meador, J.; Maxwell, R. Higgins, K.; Weissmuller, P.; Onorato, I.M. Asymptomatic hepatitis in persons who received alternative preventive therapy with pyrazinamide and ofloxacin. Clin. Infect. Dis., 1997, 24, 1264-1265.
153. Berning, S.E. The role of fluoroquinolones in tuberculosis today. Drugs, 2001, 61, 9.
154. Yew, W.W. Clinically significant interactions with drugs used in the treatment of tuberculosis. Drug Saf., 2002, 25, 111-133.
155. Foroumadi, A.; Emami, S.; Hassanzadeh, A.; Rajaee, M.; Sokhanvar, K.; Moshafi, M.H.; Shafiee, A. Synthesis and antibacterial activity of N-(5-benzylthio-1,3,4-thiadiazol-2-yl) and N-(5-benzylsulfonyl-1,3,4-thiadiazol-2-yl)piperazinyl quinolone derivatives. Bioorg. Med. Chem. Letters, 2005, 15, 4488-4492.
156. Piddock, L.J. Mechanism of quinolone uptake into bacterial cells. J. Antimicrob. Chemother., 1991, 27, 399-403.
157. Chapman J.S.; Georgopapadakou, N.H. Routes of quinolone permeation in Escherichia coli. Antimicrob. Agents Chemother., 1988, 32, 438-442.
158. Hirai, K.; Aoyama, H.; Irikura, T.; Iyobe S.; Mitsuhashi, S. Differences in susceptibility to quinolones of outer membrane mutants of Salmonella typhimurium and Escherichia coli. Antimicrob. Agents Chemother., 1986, 29, 535-538.
159. Dalhoff, A.; Schmitz, F.J. In vitro antibacterial activity and pharmacodynamics of new quinolones. Eur. J. Clin. Microbiol. Infect. Dis., 2003, 22, 203-221.
160. McCaffrey, C.; Bertasso, A.; Pace, J.; Georgopapadakou, N.H. Quinolone accumulation in Escherichia coli, Pseudomonas aeruginosa, and Staphylococcus aureus. Antimicrob. Agents Chemother., 1992, 36, 1601-1605.
161. Piddock, L.J.; Hall, M.C.; Wise, R. Mechanism of action of lomefloxacin. Antimicrob. Agents Chemother., 1990, 34, 1088-1093.
162. Brennan, P. J.; Nikaido. H. The envelope of mycobacteria. Annu. Rev. Biochem., 1995, 64, 29-63.
163. Besra, G. S.; Chatterjee, D. Lipids and carbohydrates of Mycobacterium tuberculosis. In: Bloom B R, editor. Tuberculosis: pathogenesis, protection, and control. Washington, D.C.: ASM Press; 1994, 285-306.
164. Trias, J., Benz, R. Permeability of the cell wall of Mycobacterium smegmatis. Mol. Microbiol., 1994, 14, 283-290.
165. Engelhardt, H.; Heinz, C.; Niederweis, M. A tetrameric porin limits the cell wall permeability of Mycobacterium smegmatis. J. Biol. Chem., 2002, 277, 37567-37572.
166. Wube A.A., Hüfner A., Thomaschitz C., Blunder M., Kollroser M., Bauer R., Bucar F. Design, synthesis and antimycobacterial activities of 1-methyl-2-alkenyl-4(1H)-quinolones. Bioorg. Med. Chem. 2011, 19, 567-579.
167. Guzman J.D., Wube A., Evangelopoulos D., Gupta A., Hufner A., Basavannacharya C., Md. Rahman M., Thomaschitz C., Bauer R., McHugh T.D., Nobeli I., Prieto J.M., Gibbons S., Bucar F., Bhakta S. Interaction of N-methyl-2-alkenyl-4-quinolones with ATPdependent MurE ligase of Mycobacterium tuberculosis: antibacterial activity, molecular docking and inhibition kinetics. J. Antimicrob. Chemother., 2011, 66, 1766-1772.
168. Aubry, A.; Pan, X.S.; Fisher, L.M.; Jarlier, V.; Cambau E. Mycobacterium tuberculosis DNA gyrase: interaction with quinolones and correlation with antimycobacterial drug activity. Antimicrob. Agents Chemother., 2004, 48, 1281-1288.
169. Morris, J. E.; Pan, X. S.; Fisher, L.M. Grepafloxacin, a dimethyl derivative of ciprofloxacin, acts preferentially through gyrase in Streptococcus pneumoniae: role of the C-5 group in target specificity. Antimicrob. Agents Chemother., 2002, 46, 582-585.
170. Alovero, F.L.; Pan, X.S.; Morris, J.E.; Manzo, R.H.; Fisher, L.M. Engineering the specificity of antibacterial fluoroquinolones: benzenesulfonamide modifications at C-7 of ciprofloxacin change its primary target in Streptococcus pneumoniae from topoisomerase IV to gyrase Antimicrob. Agents Chemother., 2000, 44, 320-325.
171. Gootz, T.D.; Brighty, K.E. Fluoroquinolone antibacterials: SAR mechanism of action, resistance, and clinical aspects. Med. Res. Rev., 1996, 16, 433-486.
172. Domagala, J.M. Structure-activity and structure-side-effect relationships for the quinolone antibacterials. J. Antimicrob. Chemother., 1994, 33, 685-706.
173. Tillotson, G.S. Quinolones: structure-activity relationships and future predictions. J. Med. Microbiol., 1996, 44, 320-324.
174. Klopman, G.; Li, J.Y.; Wang, S.; Pearson, A.J.; Chang, K.; Jacobs, M.R.; Bajaksouzian, S.; Ellner, J. In vitro anti-Mycobacterium avium activities of quinolones: predicted active structures and mechanistic considerations. J. Antimicrob. Agents Chemother., 1994, 8, 1794-1802.
175. Klopman, G.O.; Macina, O.T.; Levinson, M.E.; Rosenkranz, H.S. Computer automated structure evaluation of quinolone antibacterial agents. Antimicrob. Agents Chemother., 1987, 31, 1831-1840
176. Klopman, G.; Wang, S.; Jacobs, M.R.; Ellner, J.J. Anti-Mycobacterium avium activity of quinolones: structure-activity relationship studies. J. Antimicrob. Agents Chemother., 1993, 37, 1807-1815.
177. Neu, H.C. Chemical evolution of the fluoroquinolone antimicrobial agents. Am. J. Med., 1989, 87, 2-9.
178. Bryskier, A.; Chantot, J.F. Classification and structure-activity relationships of fluoroquinolones. Drugs, 1995, 49, 16-28.
179. Brighty, K.E.; Gootz, T.D. The chemistry and biological profile of trovafloxacin. J. Antimicrob. Chemother., 1997, 39, 1-14.
180. Zhao, X.; Xu, C.; Domagala, J.; Drlika, K. DNA topoisomerase targets of the fluoroquinolones: a strategy for avoiding bacterial resistance. Proc. Natl. Acad. Sci., 1997, 94, 13991-13996.
181. Zhao, B.Y.; Pine, B.Y.; Domagala, J.; Drlika, K. Fluoroquinolone action against clinical isolates of Mycobacterium tuberculosis: effects of a C-8 methoxyl group on survival in liquid media and in human macrophages. Antimicrob. Agents Chemother., 1999, 43, 661-666.
182. Zhao T.; Drlica, X.K. Gatifloxacin activity against quinoloneresistant gyrase: allele-specific enhancement of bacteriostatic and bactericidal activities by the C-8-methoxy group. Antimicrob. Agents Chemother., 1999, 43, 2969-2974.
183. Mizuki, Y.; Fujiwara, I.; Yamaguchi, T. Pharmacokinetic interactions related to the chemical structures of fluoroquinolones. J. Antimicrob. Chemother., 1996, 37, 41-55.
184. Foroumadi, A.; Emami, S.; Mehni, M.; Moshafi M.H.; Shafiee, A. Synthesis and antibacterial activity of N-[2-(5-bromothiophen-2-yl)-2-oxoethyl]and N-[(2-5-bromothiophen-2-yl)-2-oximinoethyl]derivatives of piperazinyl quinolones. Bioorg. Med. Chem. Letters, 2005, 15, 4536-4539.
185. Domagala, J.M.; Heifetz, C.L.; Hutt, M.P.; Mich, T.F.; Nichols, J.B.; Solomon M.; Worth, D.F. 1-Substituted 7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids. New quantitative structure-activity relationships at N1 for the quinolone antibacterials. J. Med. Chem., 1988, 31, 991-1001.
186. Chu, D.T.W.; Fernandes, P.B.; Claiborne, A.K.; Pihuleac, E.; Nordeen, C.W.; Maleczka, R.E.; Pernet, A.G. Synthesis and structureactivity relationships of novel arylfluoroquinolone antibacterial agents. J. Med. Chem., 1985, 28, 1558-1564.
187. Domagala, J.M.; Hanna, L.D.; Heifetz, C.L.; Hutt, M.P.; Mich, T.F.; Sanchez, J.P.; Solomon. M. New structure-activity relationships of the quinolone antibacterials using the target enzyme. The development and application of a DNA gyrase assay. J. Med. Chem., 1986, 29, 394-404.
188. Feng L.S., Liu M.L., Wang B., Chai Y., Hao X.Q., Meng S., Guo H.Y. Synthesis and in vitro antimycobacterial activity of balofloxacin ethylene isatin derivatives. Eur. J. Med. Chem. 2010, 45, 3407-3412.
189. Zhao, G.; Miller, M.J.; Franzblau, S.; Wanb B.; Möllmann, U. Syntheses and studies of quinolone-cephalosporins as potential anti-tuberculosis agents. Bioorg. Med. Chem. Letters, 2006, 16, 5534-5537.
190. Sbardella, G.; Mai, A.; Artico, M.; Setzu, M.G.; Poni G.; La Colla, P. New 6-nitroquinolones: synthesis and antimicrobial activities. Il Farmaco, 2004, 59, 463-471.
191. Shindikar, A.V.; Viswanathan, C.L. Novel fluoroquinolones: design, synthesis, and in vivo activity in mice against Mycobacterium tuberculosis H37Rv. Bioorg. Med. Chem. Lett., 2005, 15, 1803-1806.
192. Nilius, A.M.; Shen, L.L.; Hensey-Rudloff, D., Almer, L.S.; Beyer, J.M.; Balli, D.J.; Cai, Y.; Flamm R.K. In vitro antibacterial potency and spectrum of ABT-492, a new fluoroquinolone. Antimicrob. Agents Chemother., 2003,47, 3260-3269.
193. Tomioka, H.; Sato, K.; Akaki, T.; Kajitani, H.; Kawahara, S.; Sakatani, M. Comparative in vitro antimicrobial activities of the newly synthesized quinolone HSR-903, sitafloxacin (DU-6859a), gatifloxacin (AM-1155), and levofloxacin against Mycobacterium tu berculosis and Mycobacterium avium complex. Antimicrob. Agents Chemother, 1999, 43, 3001-3004.
194. Vieira L.M.M., de Almeida M.V., Lourenço M.C.S., Bezerra F.A.F.M., Fontes A.P.S. Synthesis and antitubercular activity of palladium and platinum complexes with fluoroquinolones. Eur. J. Med. Chem., 2009, 44, 4107-4111.
195. Carta, A.; Zanetti, S. Derivati triazolochinolonici ad attività antimicobatterica. I. patent, Mi2007A000455. March 7, 2007.
196. Carta, A.; Palomba, M.; Paglietti, G.; Molicotti, P.; Paglietti, B.; Cannas, S.; Zanetti, S. [1,2,3]Triazolo[4,5-h]quinolones. A new class of potent antitubercular agents against multidrug resistant Mycobacterium tuberculosis strains. Bioorg. Med. Chem. Lett., 2007, 17, 4791-4794.
197. Carta A., Piras S., Palomba M., Jabes D., Molicotti P., Zanetti S. Anti-mycobacterial activity of quinolones. Triazoloquinolones a new class of potent anti mycobacterial agents. Anti-infective agents in Medicinal Chemistry, 2008, 7, 134-147.
198. Carta A., Palomba M., Briguglio I., Corona P., Piras S., Jabes D., Guglierame P., Molicotti P., Zanetti S. Synthesis and antimycobacterial activities of triazoloquinolones. Eur. J. Med. Chem. 2011, 46 (1), 320-326.
199. Ardito, F.; Posteraro, M.; Sanguinetti, M.; Zanetti, S.; Fadda, G. Evaluation of BACTEC Mycobacteria Growth Indicator Tube (MGIT 960) Automated System for Drug Susceptibility Testing of Mycobacterium tuberculosis. J. Clin. Microbiol., 2001, 39, 4440-4444.